Biogen
NEWS
Biogen announced topline results from the Phase III VALOR trial of tofersen for superoxide dismutase 1 amyotrophic lateral sclerosis.
It was yet another busy week for clinical trial announcements. Take a look.
The 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis ran from October 13 to 15, with companies globally presenting cutting-edge studies on MS.
According to CNN, Califf is being vetted by the administration of Joe Biden, who served as vice president to Obama.
At the virtual Congress of the ECTRIMS meeting this week, multiple companies present data for ongoing studies of therapies for multiple sclerosis. BioSpace takes a look at some of the data.
Sage Therapeutics and Biogen announced positive results from their ongoing clinical trials on the efficacy and safety of zuranolone in treating major depressive disorder and postpartum depression.
Biogen agreed to pay $22 million in response to allegations that it violated the False Claims Act, and now, life insurance company Humana is suing Biogen over a similar scheme.
The United States has seen companies launching left and right. Check out the top 10 biopharma Series A rounds in the U.S. so far this year.
The Neurology Center posted a notice, saying, “At this time, the NCPA physicians will not be recommending this treatment for any of its patients.”
JOBS
IN THE PRESS
